Nerdy Science Blog

Ranjit Barshikar wrote an article regarding to the future of pharmaceutical industry in Asia.

20th Anniversary Special Feature: the rise of Asia

India, China and Singapore are expected to become leaders in the pharmaceutical sector. India and China have become major suppliers of APIs, with India also exporting high volumes of pharmaceutical dosage products. South Korea, Malaysia, Thailand, Taiwan and Hong Kong are also creating strong pharmaceutical bases, although these markets are mainly dominated by MNCs. More clinical trials are also being conducted in Asia and India has taken the lead in clinical trial outsourcing. Asia is now returning to GDP levels of the 19th century when it was at its highest (12%). According to Goldman Sachs, India is expected to become the world’s third largest economy by 2050. Many MNCs are investing and building their businesses in China and India, and it is expected that total pharmaceutical sales in China (at current levels of approximately $14 billion [€9 billion]) will double to $28 billion (€18 billion) by 2010.(1)

Ranjit pointed out the factors that cause the growth of Asian market are:

• population factors
• clinical trials
• R&D innovation
• generics companies
• cost advantages
• regulatory support